Scientists talked about the effect of HIV protein and morphine on brain cells
In experiments on cells and mice, the combination of the HIV Tat protein with morphine increased the signs of DNA damage and inflammation. Dimethyl fumarate, which is used for multiple sclerosis, has weakened some of these changes. In a separate experiment, mice treated with the drug performed better on an object recognition test. About what signs of damage were found in the tissues of the human brain, what experiments with dimethyl fumarate have shown, and what questions remain before human trials, see the Izvestia article.
Why do people study memory and attention with HIV?
Antiretroviral therapy suppresses the spread of HIV, reduces viral load and allows people with this diagnosis to live longer. Some patients still have difficulty remembering, concentrating, and planning their daily activities. With the spread of effective treatment, researchers are more likely to describe less pronounced cognitive impairments that can affect daily life.
In a 2025 study in Frontiers in Immunology, scientists separately analyzed postmortem frontal cortex samples from 18 people in whom therapy suppressed viral load in the blood. Their samples were more likely to contain cells with markers of inflammatory activity than in the tissues of donors without HIV.
The recommendations of an international team of specialists published in The Lancet HIV in 2023 suggest taking into account the consequences of brain damage before starting treatment, possible ongoing exposure to HIV, and other causes of cognitive impairment. For such an assessment, a person's complaints, medical history, and examination results are important.
How cells, mice, and human tissue were studied
Researchers from Texas A&M University, the University of Florida, and McLean Hospital, affiliated with Harvard Medical School, participated in the work. The team studied how the HIV protein Tat and the opioid analgesic morphine affect brain cells when they act separately and together.
In the laboratory, the scientists worked with microglia, immune cells in the brain that respond to damage to nervous tissue and are involved in the inflammatory response. In mice, we studied how the presence of the Tat protein and the effects of morphine affect brain tissue. The scientists also tested how animals recognize familiar and new objects.
The researchers also compared postmortem samples of the frontal cortex of people with HIV and donors without HIV. The first group included six people aged 30 to 60 years with confirmed HIV encephalitis. All of them received combined antiretroviral therapy for at least six months. These samples allowed us to check which of the laboratory signs are found in human brain tissue.
How DNA damage is related to inflammation
In the cell nucleus, DNA is stacked around histone proteins. The degree of packaging affects access to individual parts of the genome, and chemical tags on histones help regulate this process. When Tat and morphine were combined in laboratory models, the ratio of such labels changed. The authors interpreted this as a sign that some densely packed regions of chromatin have become more accessible.
At the same time, the signals of the response to DNA damage increased. The researchers found more yH2AX, a modified form of histone, which is used as a marker of this response. The level of some of the proteins involved in DNA repair decreased. The authors also recorded an increase in the inflammatory signals of the innate immune system.
"When HIV and morphine act simultaneously, the brain finds itself in a vicious cycle of DNA damage and inflammation," explained Kartik Chennakesavan, first author of the work, a researcher at the College of Pharmacy at Texas A&M University, describing the results of laboratory models.
In postmortem frontal cortex samples from people with HIV encephalitis, scientists have found some of the same signs. These donors had more yH2AX and fewer two DNA repair proteins, ERCC2 and ERCC3, than donors without HIV. The researchers evaluated the effects of morphine in cellular experiments and in mice.
What has the experience with dimethyl fumarate shown?
The researchers chose dimethyl fumarate because of its ability to enhance cell protection against oxidative stress. In experiments, against the background of its use, individual inflammatory signals weakened. The levels of some DNA repair proteins and chemical tags on histones approached those of the control groups.
A separate cellular experience indicated a connection with the DNA damage response system. When the researchers reduced the amount of H2AX — histone, the modified form of which was measured as a marker of damage — some of the inflammatory signals also weakened. At the same time, the chemical labels on the histones changed.
A new object recognition test was used to evaluate the memory of mice. If an animal remembers a familiar object, it usually takes longer to explore a new one. The result was lower in mice with Tat protein than in the control group. The combination of Tat with morphine in this test did not result in a statistically significant additional deterioration.
In an experiment where dimethyl fumarate was used prophylactically, mice with Tat performed better on the object recognition task. This result refers to a single memory test. The authors note that it remains to be seen how stable the effect is and how the drug affects other indicators of brain function.
What needs to be tested in humans
The US Food and Drug Administration (FDA) has approved dimethyl fumarate for the treatment of recurrent forms of multiple sclerosis in adults. The instructions indicate a decrease in the number of lymphocytes among the possible undesirable effects. When studying the drug in people with HIV, it will be necessary to assess how it affects immune performance against the background of antiretroviral therapy.
"This work provides a new perspective on HIV-related brain damage. Dimethyl fumarate has already been approved for use in other indications, so it can be considered as a candidate for testing in people with HIV—related cognitive impairments," said Samikkannu Tangavel, associate professor of Pharmaceutical Sciences at Texas A&M University, head of the study.
The team intends to study the early signs of DNA damage and test their findings on additional human tissue samples. To evaluate the possible benefits of dimethyl fumarate in people with HIV, a clinical trial will be needed to measure participants' memory and attention and evaluate the drug's safety.
Переведено сервисом «Яндекс Переводчик»